Sunshine Biopharma, Inc. (SBFM)
| Previous Close | 0.8375 |
| Open | 0.9227 |
| Bid | 0.8769 x 6000 |
| Ask | 0.8601 x 5000 |
| Day's Range | 0.8101 - 0.9227 |
| 52 Week Range | 0.7500 - 140.0000 |
| Volume | |
| Avg. Volume | 1,964,105 |
| Market Cap | 854,200 |
| Beta (5Y Monthly) | -1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.0000 |
| Earnings Date | May 09, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 300.00 |
ACCESSWIRESunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that ...
- ACCESSWIRE
Sunshine Biopharma Announces Reverse Stock Split
NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology ...
- ACCESSWIRE
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
Sales Grew at an Average Rate of 14% Per Quarter During the Year NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety ...
